SCHEMBL1643554

SCHEMBL1643554

CCNc1ccc([C@@H](C)NC(=O)c2ccc3cc(C(C)(C)C)ccc3c2)nc1C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.40
CYP17A1 P05093 5/20 0.39
CYP3A4 P08684 5/20 0.39
IDO1 P14902 1/20 0.36
KCNH2 Q12809 1/20 0.36
PDE2A O00408 1/20 0.36
GAA P10253 2/20 0.35
HTT P42858 2/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
CACNA1I Q9P0X4 1/20 0.35
PTPN1 P18031 2/20 0.35
ALPL P05186 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
B3GNT2 Q9NY97 2/20 0.35
PPARG P37231 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285045 0.85 PTPN1 (0.42) NR1H4CYP17A1CYP3A4PTPN1
SCHEMBL1643125 0.84 CYP17A1 (0.40) NR1H4CYP17A1CYP3A4PDE2ACACNA1I
SCHEMBL1644338 0.82 NR1H4 (0.48) NR1H4PDE2AALDH1A1ROCK2ROCK1
SCHEMBL1644460 0.78 NR1H4 (0.38) NR1H4CYP17A1CYP3A4PDE2AGAA
SCHEMBL1644853 0.75 PDE2A (0.43) CYP17A1CYP3A4PDE2AB3GNT2
SCHEMBL14378392 0.74 CYP17A1 (0.41) NR1H4CYP17A1CYP3A4PDE2ACACNA1I
SCHEMBL1645545 0.73 PDE2A (0.42) NR1H4CYP3A4PDE2AALDH1A1PPARG
SCHEMBL21467201 0.73 CYP17A1 (0.57) NR1H4CYP17A1CYP3A4ALDH1A1PTPN1
SCHEMBL2903698 0.72 NR1H4 (0.56) NR1H4CYP17A1CYP3A4PDE2AALDH1A1
SCHEMBL1643047 0.72 NR1H4 (0.41) NR1H4PDE2AGAAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 NR1H4 732/4885CYP17A1 4396/4885CYP3A4 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.